Across TCGA pan-cancer cohorts, FABP5 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FABP5 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher FABP5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FABP5 expression acts as an unfavorable survival marker.
ESCA are the cancer types where FABP5 Mutation most reproducibly stratifies survival.